United States Influenza Pharmaceutical Markets


Regular Price: USD 3,950.00

Special Price USD 2,765.00

30% OFF

* Required Fields

Regular Price: USD 3,950.00

Special Price USD 2,765.00


Be the first to review this product

Table of Contents

United States Influenza Pharmaceutical Markets, Executive SummaryIntroduction to the U.S. Influenza Antiviral and Vaccine MarketsObjectives and PurposeReport Scope and SegmentationReport Structure Summary of Major FindingsOverview—Influenza Antiviral MarketOverview—Vaccine MarketAnalysis by Major SegmentCompetitive AnalysisMarket EntrantsMarket ExitsUnited States Influenza Pharmaceutical Markets, Market Engineering Research MethodologyResearch ScopeObjectives and PurposeMarket Engineering Forecasting MethodologyOverviewStrategic Significance of the Market Engineering ForecastJudging Credibility and Accuracy of Market Engineering ForecastsForecast AssumptionsUnited States Influenza Pharmaceutical Markets, Industry ChallengesIdentification of Challenges Facing the U.S. Influenza Pharmaceutical MarketIdentification of Challenges Facing the U.S. Influenza Pharmaceutical MarketInfluenza Antiviral MarketInfluenza Antiviral MarketShifts in Healthcare Policies Challenge Ability of Antivirals to Penetrate Successfully the Elderly Segments of the Population Defining and Specifying Role of Antivirals Within Influenza Management in Order to Justify High Price of Treatments Relative to Current Treatment Options Changing Physician Behavior Within the Arena of Influenza Treatment and Management Vital to Product’s SuccessChanging the Patient’s Perception of Influenza Treatment Options Generates RevenuesEducating Patients and Physicians on the Benefits and Limitations of the New Antiviral Drugs Boosts Market AcceptanceExecuting Clinical Trials That Prove Efficacious in High-Risk Patients Bolsters Influenza Antiviral Market AcceptanceImproving Influenza Surveillance Systems in Order to Identify Influenza Outbreaks More Quickly and Efficiently Creates Need for AntiviralsInfluenza Vaccine MarketInfluenza Vaccine MarketEducating the General Public on the Benefits of the Influenza Vaccine Increases UptakeComplex Vaccine Manufacturing and Development Protocols Lead to Inconsistencies in Amount and Quality of Vaccines Produced Each YearPrice of New Technological Advances in Vaccine Design and Development Needs to Be Accepted Over That of Traditional, Inexpensive VaccinesIncreasing Vaccination Rates in Traditionally Underprivileged and Underrepresented Populations Raises Level of ComplianceAddressing and Formulating Priorities in Vaccine Administration Within the Context of a Cost-to-Benefit Analysis Bring Awareness to the Importance of Influenza Vaccination Market Engineering Research for the U.S. Influenza Antivirals Market 1996-2006Total Market Segment AnalysisOverview—Influenza Antivirals DefinitionsScope/SegmentationHistory/Overview/Introduction of InfluenzaInfluenza: The BasicsInfluenza Viral Replication: Three Parts Nomenclature Influenza Virus Strain EvolutionHistory of Influenza Antivirals and Their Mechanisms of ActionInfluenza Therapies: Future Mechanisms of ActionMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemMarket Engineering Unit and Revenue Forecasts (1999-2006)Market DriversMarket RestraintsMarket Demand Analysis—Two Markets: Therapeutic and ProphylacticCompetitive AnalysisPricing AnalysisCompetitive StructureCompetitive StructureAlliancesMarket Share AnalysisProduct AnalysisFuture OutlookProducts in Clinical TrialsMarket Engineering Research for the U.S. Influenza Vaccine Market 1996-2006Market Overview and DefinitionsOverviewDefinitionMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemMarket DriversMarket DriversRecommendations by State and Federal Organizations Boost Vaccination Rates Corporate Vaccination Programs Drive Vaccination Rates in Healthy PopulationsNew Technologies Drive Average Vaccine PricesNew Market Contenders Aim to Increase Vaccination RatesRevised Recommendations by State and Federal Organizations Increase Target Populations Influenza Management Boosts Public Awareness of the Economic and Health Benefits of Getting VaccinatedGovernment-Sponsored Programs for Free Vaccinations Increase Availability of Influenza VaccineMarket RestraintsMarket RestraintsLow-Margin Market Deters Extensive Marketing ExpensesInjectable Influenza Vaccine Limits Acceptance in the Healthy Pediatric MarketQuestions Regarding Efficacy of Currently Available Vaccines by End-UsersPerception That the Vaccine May Cause Influenza Limits Vaccination RatesHurdles Viewed in the Vaccination Process in Healthy PopulationsLimited Reimbursement Policies Restrict Market Penetration of Expensive Novel VaccinesConstraints on Vaccine Volume and Price Force Limited Revenue Growth Under Contract Negotiations Market Engineering Revenue Forecasts (1996-2006)Patient Population (Demand Analysis)Pricing AnalysisRevenuesDistribution StructureDistribution StructureTechnology TrendsAlternate Routes of Vaccine Delivery Influenza Vaccine AdjuvantsRecombinant Manufacturing MethodsDNA VaccinesCompetitive AnalysisCompetitive AnalysisCompetitive StructureMarket Share AnalysisMarket Share Winners and WhyMarket Share Losers and WhyProducts on the MarketProducts in Clinical TrialsUnited States Influenza Pharmaceutical Markets, Market Engineering StrategyMarket Engineering Strategic RecommendationsMarket Engineering Strategic RecommendationsCorporate Management Marketing DepartmentResearch and DevelopmentIndustry Strategy—A SummaryMarket Engineering Awards for the Influenza Pharmaceutical MarketFrost & Sullivan's 2000 Market Engineering AwardsFrost & Sullivan's 2000 Market Engineering AwardsMarket Engineering AwardsMarket Engineering AwardsAward Category: Product Differentiation Award Category: Product Innovation Award Category: Strategic Alliance Leadership

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.